Immunolocalization of ras oncogene p21 in human liver diseases

James A. Radosevich, Karen A. Gould, George K. Koukoulis, G. Kenneth Haines, Steven T. Rosen, I. Lee, Victor E. Gould

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Fifty-five cases representing a spectrum of disease states of the human liver and 10 normal liver controls were examined for the presence of the ras oncogene product p21. Conventional formalin-fixed, paraffin-embedded sections were immuno-stained by the avidin-biotin complex method with the broadly reactive ras p21 monoclonal antibody (Mab) RAP-5. The specificity of the reactions was confirmed by immunostaining selected samples with Mab Y13-259. In the normal liver, virtually no hepatocytic immunostaining was noted. Variable, often extensive, and convincing immunoreactions were noted in diverse forms of hepatitis, cirrhosis, and allograft rejection; the strongest immunostaining was found in samples of focal nodular hyperplasia. Hepatic adenomas and hepatocellular carcinomas showed unevenly distributed, moderate to weak reactions or no reaction at all; cholangiocar-cinomas did not immunostain. In reactive but non-transformed liver cell populations, enhanced p21 ras reactions seemed to correlate with the severity of the injury and the intensity of the proliferative response. The uneven and comparatively weak ras p21 reactions noted in adenomas and carcinomas suggest that this oncogene product may be involved only transitorily in their transformation processes and possibly may not be involved in certain variants thereof.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalUltrastructural Pathology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 1993

Fingerprint

oncogenes
ras Genes
liver
Liver
Liver Diseases
Proto-Oncogene Proteins p21(ras)
Monoclonal antibodies
antibodies
Adenoma
Oncogene Protein p21(ras)
cancer
Monoclonal Antibodies
Focal Nodular Hyperplasia
hepatitis
biotin
Formaldehyde
Paraffins
Avidin
Oncogene Proteins
paraffins

Keywords

  • Immunohistochemistry
  • Liver diseases
  • Liver tumors
  • Monoclonal antibodies
  • Ras oncogene

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Structural Biology

Cite this

Radosevich, J. A., Gould, K. A., Koukoulis, G. K., Haines, G. K., Rosen, S. T., Lee, I., & Gould, V. E. (1993). Immunolocalization of ras oncogene p21 in human liver diseases. Ultrastructural Pathology, 17(1), 1-8. https://doi.org/10.3109/01913129309015397

Immunolocalization of ras oncogene p21 in human liver diseases. / Radosevich, James A.; Gould, Karen A.; Koukoulis, George K.; Haines, G. Kenneth; Rosen, Steven T.; Lee, I.; Gould, Victor E.

In: Ultrastructural Pathology, Vol. 17, No. 1, 01.01.1993, p. 1-8.

Research output: Contribution to journalArticle

Radosevich, JA, Gould, KA, Koukoulis, GK, Haines, GK, Rosen, ST, Lee, I & Gould, VE 1993, 'Immunolocalization of ras oncogene p21 in human liver diseases', Ultrastructural Pathology, vol. 17, no. 1, pp. 1-8. https://doi.org/10.3109/01913129309015397
Radosevich, James A. ; Gould, Karen A. ; Koukoulis, George K. ; Haines, G. Kenneth ; Rosen, Steven T. ; Lee, I. ; Gould, Victor E. / Immunolocalization of ras oncogene p21 in human liver diseases. In: Ultrastructural Pathology. 1993 ; Vol. 17, No. 1. pp. 1-8.
@article{ecaa224014484509bdf625ca8dc843fd,
title = "Immunolocalization of ras oncogene p21 in human liver diseases",
abstract = "Fifty-five cases representing a spectrum of disease states of the human liver and 10 normal liver controls were examined for the presence of the ras oncogene product p21. Conventional formalin-fixed, paraffin-embedded sections were immuno-stained by the avidin-biotin complex method with the broadly reactive ras p21 monoclonal antibody (Mab) RAP-5. The specificity of the reactions was confirmed by immunostaining selected samples with Mab Y13-259. In the normal liver, virtually no hepatocytic immunostaining was noted. Variable, often extensive, and convincing immunoreactions were noted in diverse forms of hepatitis, cirrhosis, and allograft rejection; the strongest immunostaining was found in samples of focal nodular hyperplasia. Hepatic adenomas and hepatocellular carcinomas showed unevenly distributed, moderate to weak reactions or no reaction at all; cholangiocar-cinomas did not immunostain. In reactive but non-transformed liver cell populations, enhanced p21 ras reactions seemed to correlate with the severity of the injury and the intensity of the proliferative response. The uneven and comparatively weak ras p21 reactions noted in adenomas and carcinomas suggest that this oncogene product may be involved only transitorily in their transformation processes and possibly may not be involved in certain variants thereof.",
keywords = "Immunohistochemistry, Liver diseases, Liver tumors, Monoclonal antibodies, Ras oncogene",
author = "Radosevich, {James A.} and Gould, {Karen A.} and Koukoulis, {George K.} and Haines, {G. Kenneth} and Rosen, {Steven T.} and I. Lee and Gould, {Victor E.}",
year = "1993",
month = "1",
day = "1",
doi = "10.3109/01913129309015397",
language = "English (US)",
volume = "17",
pages = "1--8",
journal = "Ultrastructural Pathology",
issn = "0191-3123",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Immunolocalization of ras oncogene p21 in human liver diseases

AU - Radosevich, James A.

AU - Gould, Karen A.

AU - Koukoulis, George K.

AU - Haines, G. Kenneth

AU - Rosen, Steven T.

AU - Lee, I.

AU - Gould, Victor E.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Fifty-five cases representing a spectrum of disease states of the human liver and 10 normal liver controls were examined for the presence of the ras oncogene product p21. Conventional formalin-fixed, paraffin-embedded sections were immuno-stained by the avidin-biotin complex method with the broadly reactive ras p21 monoclonal antibody (Mab) RAP-5. The specificity of the reactions was confirmed by immunostaining selected samples with Mab Y13-259. In the normal liver, virtually no hepatocytic immunostaining was noted. Variable, often extensive, and convincing immunoreactions were noted in diverse forms of hepatitis, cirrhosis, and allograft rejection; the strongest immunostaining was found in samples of focal nodular hyperplasia. Hepatic adenomas and hepatocellular carcinomas showed unevenly distributed, moderate to weak reactions or no reaction at all; cholangiocar-cinomas did not immunostain. In reactive but non-transformed liver cell populations, enhanced p21 ras reactions seemed to correlate with the severity of the injury and the intensity of the proliferative response. The uneven and comparatively weak ras p21 reactions noted in adenomas and carcinomas suggest that this oncogene product may be involved only transitorily in their transformation processes and possibly may not be involved in certain variants thereof.

AB - Fifty-five cases representing a spectrum of disease states of the human liver and 10 normal liver controls were examined for the presence of the ras oncogene product p21. Conventional formalin-fixed, paraffin-embedded sections were immuno-stained by the avidin-biotin complex method with the broadly reactive ras p21 monoclonal antibody (Mab) RAP-5. The specificity of the reactions was confirmed by immunostaining selected samples with Mab Y13-259. In the normal liver, virtually no hepatocytic immunostaining was noted. Variable, often extensive, and convincing immunoreactions were noted in diverse forms of hepatitis, cirrhosis, and allograft rejection; the strongest immunostaining was found in samples of focal nodular hyperplasia. Hepatic adenomas and hepatocellular carcinomas showed unevenly distributed, moderate to weak reactions or no reaction at all; cholangiocar-cinomas did not immunostain. In reactive but non-transformed liver cell populations, enhanced p21 ras reactions seemed to correlate with the severity of the injury and the intensity of the proliferative response. The uneven and comparatively weak ras p21 reactions noted in adenomas and carcinomas suggest that this oncogene product may be involved only transitorily in their transformation processes and possibly may not be involved in certain variants thereof.

KW - Immunohistochemistry

KW - Liver diseases

KW - Liver tumors

KW - Monoclonal antibodies

KW - Ras oncogene

UR - http://www.scopus.com/inward/record.url?scp=0027399001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027399001&partnerID=8YFLogxK

U2 - 10.3109/01913129309015397

DO - 10.3109/01913129309015397

M3 - Article

C2 - 8381245

AN - SCOPUS:0027399001

VL - 17

SP - 1

EP - 8

JO - Ultrastructural Pathology

JF - Ultrastructural Pathology

SN - 0191-3123

IS - 1

ER -